Introduction
Medullary thyroid cancer (MTC) is a rare tumor entity (5-10% of all thyroid cancers) [1, 2] . It has a variable course and may result in a variety of different symptoms, also caused by abnormal hormone production. For the treatment of patients with aggressive, metastatic and symptomatic MTC not amena ble to surgery, no systemic therapy was approved in Germany until early 2012. For patients affected by this tumor, only pal liative therapies -most of them offlabel -and best support ive care (BSC) were available.
Currently, the structure of health services provided to pa tients under BSC in this population is not defined. Moreover, there are no recommendations as to which BSC measures should be considered in MTC patients. Different definitions of BSC are available in the literature. According to the Euro pean Organisation for Research and Treatment of Cancer, BSC is defined as 'supportive care with a multiprofessional attention to the individual's overall physical, psychosocial, spiritual and cultural needs, and should be available at all stages of the illness, for patients of all ages, and regardless of the current intention of any anticancer treatment' [3] .
In the existing literature, no common consensus has been reached so far. According to Salzwimmer [4] , BSC includes the following general aspects: -improvement of the prerequisites for performing oncologi cal therapies -reduction of the incidence of side effects of cytotoxic therapies -maintenance or improvement of the patients' quality of life Keywords Medullary thyroid cancer · Delphi panel · Best supportive care · Costs · Germany · Health economics Summary Background: Medullary thyroid cancer (MTC) is a rare tumor entity. The contents of best supportive care (BSC) have not been defined in advanced MTC. The objective of this work is to describe the epidemiology, the treatment patterns with respect to symptom management, as well as palliative treatment and associated costs. Method: A Delphi panel with 9 clinical experts experienced in treating MTC was conducted to obtain details on the epidemiology of MTC and to gain insights into the therapeutic options considered for BSC in advanced MTC in Germany. Unit costs were applied to the described resources from the perspective of the German National Healthcare System in 2011. Results: The annual incidence of MTC in Germany was estimated at about 220. 32% of all patients were estimated to have aggressive/symptomatic MTC, with an estimated mean survival of 36.7 months (median: 36 months). The core element of BSC is relief of symptoms to maintain quality of life. The total mean cost of BSC per patient/year was estimated at € 9,248, lifetime cost at € 28,283. Conclusion: There was consistent agreement within the panel on the epidemiology of MTC and on the structure of the provided therapeutic measures for BSC in advanced MTC, also defining the management of symptoms as a crucial goal of treatment.
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Best Supportive Care and Its Costs in Advanced Medullary Thyroid Cancer 317 katalog) [9] , which provides an overview of all reimbursable remedies available within the German statutory health insurance. Costs for enteral nutrition, palliative surgery, psychotherapy, and oxygen support measures are based on the current German Uniform Valuation Scheme (Gebüh renordnung Einheitlicher Bewertungsmaßstab: EBM 2011) [10] for additional services provided in the ambulatory setting, the current Ger man diagnosisrelated groups (DRG) catalogue (2012), the LauerTaxe (German Red Book), and on manufacturer prices for medical devices as applicable.
Direct nonmedical costs (e.g. costs for transportation to a hospital or outpatient clinic), indirect costs, and intangible costs due to impacts on quality of life (e.g. pain or distress) were not included in the analyses. Furthermore, outofpocket costs of patients were not integrated.
To calculate the average costs of BSC in advanced MTC, all cost elements per DDD were weighted by the proportion of their use in BSC as reported by the Delphi panel. All costs were calculated from the per spective of a German healthcare insurance.
Results

Epidemiology
On the basis of the results of the panel, the annual inci dence of MTC in Germany is estimated at about 220 cases. According to the panel, up to 32% of the patients diagnosed with MTC have an aggressive and symptomatic tumor (71 cases), which is nonresectable, locally advanced, or metasta sized. These patients have a mean life expectancy of 36.7 months (median: 36 months). In the end stage of the disease, most of these patients (64%) are taken care of at home, either by ambulatory care and/or by caregivers. About 29% of the finalstage patients are treated in an inpatient setting, with 20% in an internal medicine ward, 9% in a palliative care unit, and 8% in a hospice. The end stage of the disease lasts for around 15 weeks, on average.
Treatment Options in a Palliative Setting
According to the statements of the panel, BSC in non resectable, locally advanced or metastasized MTC mainly focuses on the relief of symptoms associated with the tumor or its metastases. Since even in an advanced MTC stage overall survival is fairly long compared to other cancers, this approach is of paramount importance to maintain the quality of life. Special emphasis should be put on maintaining the mobility of the patients and providing nutritional support. Other measures are pain therapy, antidiarrheal treatment, prevention of the wasting syndrome, skin care, and -in patients with bone me tastases -administration of bisphosphonates. Local radio therapy may be considered in cases with bones metastases and locally advanced disease with spread to the mediastinum or developed brain metastases. Hepatic metastases may be treated using transarterial chemoembolization (TACE).
Offlabel treatment with a tyrosine kinase inhibitor and inclusion in a clinical trial were also reported as options be sides BSC. According to the panel, 18% of the patients with advanced disease receive chemotherapy, 29% are treated with local radiotherapy, 54% are enrolled in clinical trials -alleviation of tumorassociated symptoms -prognostic improvement of the treatment results
As of today, the discussion is still ongoing whether systemic therapies form a part of BSC. Since until recently no standard therapy existed in MTC, all potentially feasible palliative and symptom managementoriented therapeutic measures can be defined as part of a BSC concept. It has to be noted that, in advanced MTC, symptoms resulting from excessive hormone production, e.g. diarrhea, also need to be addressed by appro priate therapies in order to maintain quality of life.
An expert panel approach was chosen to identify therapies and measures that are deemed part of BSC in MTC patients in Germany. Another objective of this study was to assess the costs of BSC in advanced MTC to form a database for future health economic research.
Methods
Delphi Panel
To identify the various components of BSC for MTC patients, the Delphi method was applied. This systematic, consensusoriented, multi level interview technique aims to combine the expertise and knowledge of individual participants to generate consensus statements on previ ously defined study subjects [5, 6] . The process is divided into successive rounds of questioning. In each round, the participants are interviewed individually and independently. Following each round, the survey re sponses are aggregated, condensed and again presented to the partici pants. During this phase, the participants are invited to review and com ment on their previous answers in light of the summarized responses. The different steps of the Delphi process are repeated until maximum agree ment is achieved. All participants remain anonymous until the end of the process.
In the present study, the questionnairebased Delphi panel was held in 2 rounds from November 2011 to January 2012, with 9 clinical experts in endocrinology and/or the treatment of MTC. The Delphi panel consisted of 6 endocrinologists, 2 nuclear medicine specialists, and 1 general oncolo gist. All participants are involved in the treatment of MTC on an aca demic and patient level, covering 7 university hospitals in Germany and taking care of approximately 132 new MTC cases (of all tumor stages) per year. The Delphi panel was accompanied by an independent methodo logical expert.
In the first round, the experts were asked about the different areas of therapy in MTC. The topics of the questionnaire covered the epidemiol ogy, the treatment options in a palliative setting, the treatment options for symptomatic BSC, and a comparison of different treatment options. Re sponses were given via email, fax, or by post.
During the second round, the participants were asked to comment on the mean results and a summary of freetext questions, to determine the final results. A predefined consensus criterion of at least 75% agreement on each topic was already reached after the second round of questioning. Further comments and divergent opinions were documented.
Costs Cost data were obtained from different sources. Costs for medication and concomitantly used drugs are based on the Arzneiverordnungs Report 2011 [7] , which is the most comprehensive (annual) report on medication costs and prescription patterns in ambulatory care in Ger many. Costs in this area are expressed in terms of the defined daily dose (DDD) [8] . The costs of occupational therapy and physiotherapy were obtained from the official reimbursement catalogue (Heilmittel Kreissl/Jacob/Führer/Karges/Luster/Lux/Mann/ Mittendorf/Schott/Spitzweg/Schmoll evaluating tyrosine kinase inhibitors, and 22% are treated using other therapies, e.g. peptide receptor radionuclide therapy. 3.5% refuse any kind of treatment besides symptomatic therapy.
Costs of Treatment
The Delphi panel defined a need for drugs, symptomatic treatment, and other healthcare measures as described in tables 1 and 2. The highest percentage of use (56.7%) was at tributed to antidiarrheals needed to treat hormoneinduced diarrhea, which can be observed in most cases of advanced MTC. Some of the patients also require additional treatment for functional gastrointestinal disorders, e.g. nausea (17.2%); some also require special enteral nutrition (16.1%), which is cost intensive. As in other advanced tumors, bone metastases and offlabel use of tyrosine kinase inhibitors is legally prob lematic and not commonly covered by health insurances, these two options were not addressed in the calculation of costs for BSC. Approximately onethird of the finalstage patients are treated as inpatients. These services in Germany are reim bursed via a DRG system for hospital stays and on a daily basis for hospice stays. Besides the included BSC items, addi tional costs for hospital or hospice stays are not included in the calculation of BSC costs. Therefore, the estimated costs of € 9,248/year most likely represent an underestimation.
There might be additional costs associated with the treat ment of MTC patients due to regular physician contacts, med ical examinations, and laboratory tests. These costs are not included in the calculation of BSC costs because of the struc ture of the German reimbursement system for outpatients. Services are covered by a more or less flat quarterly payment, which includes services in the ambulatory setting regardless of the quantity of services provided. By taking the perspective of the statutory health insurance, no accurate estimation of the fraction of services due to BSC is possible, and therefore no precise attribution of costs is feasible. Although the quarterly fees vary in different regions in Germany, they will rarely exceed € 100/patient from the perspective of the health insur ance. In case of a private health insurance, the additional cost for these services might be higher because every physician contact is reimbursed separately instead of being covered by a quarterly fee.
Not many studies have been published assessing the costs of BSC in other tumor entities. Usually, health economic eval uations or cost effectiveness studies tend to focus more on new systemic therapeutic options and not on BSC.
Nonsmallcell lung cancer (NSCLC) is the malignancy with the most comprehensive data in this respect. Araujo et al. [19] calculated € 16,112 for a 2year period of BSC (€ 8,056/ year) using a costutility model in 2008. In contrast, Isla et al. [20] in 2011 applied a Delphi panel and obtained € 3,410 as lifetime cost (median 3.5 months) of BSC in advanced NSCLC in Spain. Navaratam et al. [21] performed a database analysis including chart reviews and obtained a figure of $CAN 8,654 as total expenses for 1 period of BSC (median 13.8 weeks). There are also 2 studies using a Markov model, published in 2008 and 2010, on the lifetime total cost in hepatocellular cancer, yielding costs of $CAN 10,376 ± 1,649 and $US 7,804 ± 1,349, respectively [22, 23] . In 2008, Purmonen et al. [24] calculated the 1year expenses for BSC in metastatic renal cell carcinoma to be € 5,543, using a probabilistic decisionanalytic model. A fairly high amount for 1 year of BSC in metastatic breast cancer of $US 23,379 was found by Sorensen et al. [25] using a costofillness model.
Costs for the provision of healthcare have been increasing for years. Germany is one of the countries with the highest spending on healthcare [26, 27] , with drug costs having risen from € 19.2 billion in 1999 to € 32.4 billion in 2009 [28] . occur frequently in MTC. In order to prevent fractures and reduce pain, bisphosphonates are commonly used (27.8%) and account for a substantial fraction of the overall cost of BSC in advanced MTC.
In addition, analgetics (excluding opiates) (39.4%) and opiates (31.1%) are frequently applied. Patients occasionally require palliative radiotherapy due to progressive cervical tumors and painful metastases in bones or other sites (28.8%). Palliative surgery, especially to ensure airway patency but also to enable enteral nourishment, is necessary in 10.3% of the patients. According to the results of the panel, 18.3% of the patients receive a treatment by chemotherapy (noncurative in intention).
Total Costs per Patient and Year
The total mean costs for BSC per patient with advanced MTC were calculated on a permonth and peryear basis and are estimated to be € 760/month and € 9,248/year, respectively. Assuming a mean survival of 36.7 months, lifetime costs amount to € 28,283.
Discussion
This study assessed data on the epidemiology, treatment patterns in symptom management, palliative treatment, and the costs associated with BSC in advanced MTC in Germany.
It was shown that German experts have a consensual un derstanding of advanced MTC in terms of its epidemiology. The annual incidence of MTC was estimated at about 220. This number is in line with previously published data stating a fraction of 5-10% MTCs among all thyroid cancers [11, 12] , which are estimated to have an annual incidence of 5,300 in Germany [13] . However, in other publications, the fraction of MTC is only 1-3% [14] . According to the expert panel, up to 32% of the patients diagnosed with MTC have an aggressive and symptomatic tumor, which can be nonresectable, locally advanced, or metastasized. Exact data on this topic are lack ing, but a German survey found 45% of patients in stage III and 8% in stage IV, at initial presentation (per definition, all of these patients were advanced and/or metastasized but not necessarily symptomatic or progressive) [15] .
In general, the suggestions of the panel were in line with published guidelines for treating MTC from the American Thyroid Association (ATA) [16] and the European Society for Medical Oncology (ESMO) [17] and with the recently pub lished guidelines of the European Thyroid Association for metastatic MTC [18] . However, treatment of patients in ad vanced stages only constitutes a small fraction of these guide lines, and the level of evidence for specific recommendations on single measures is usually not very high. Both guidelines advocate the inclusion of patients in clinical trials with new targeted therapies, which was also suggested by the panel ex perts. Since the participation in trials is not always possible In order to meet this challenge in the longer term, an addi tional dimension aside from clinical efficacy is increasingly being incorporated into medical decisionmaking: the assess ment of costs relative to benefits by using health economic decisionmaking models. In Germany, following the latest healthcare reform (the Drug Market Reform Act, Arznei mittelmarktneuordnungsgesetz, AMNOG), a structured as sessment of the additional clinical benefit of a new drug is carried out by the Federal Joint Committee (Gemeinsamer Bundesausschuss, GBA) [29] . Hence, there is an urgent need for the definition and description of existing care patterns (e.g. BSC) in different oncological indications and for the evalua tion of costs in these different treatment settings, in order to build a set of baseline data for future health economic studies for new treatment options in combinations or also versus BSC. The results of this Delphi consensus are one important step to reach these goals.
Limitations
A limitation of this study is the lack of the surgical perspec tive. The majority of MTC patients in an early state of the disease are seen by a surgeon, who plays a major role in the initial therapy, staging, and decisions on further treatment steps. Thus, the estimation of incidence, and likewise the pro portion of advanced cases, might be underestimated. Also, the role of palliative surgery in order to relieve pain and safe guard airways and oral feeding might be more prominent from a surgical perspective.
As in many oncologic indications and also as a limitation in this study, the terms 'symptomatic' and 'aggressive' in this sur vey were not further specified and, hence, may have been de fined in different ways by the experts. Commonly, 'symptom atic' refers to a patient being affected by the tumor or its therapy. But, depending on how thoroughly a treating physi cian investigates a patient, tumorassociated symptoms may be found in almost all patients. Similarly, 'aggressive' is not defined at all. Even metastasized MTC has a 10year survival rate of 40% according to the Surveillance, Epidemiology and End Results (SEER) registry (n = 1,252). However, 40% of the patients with metastatic disease die within 2 years [30] .
Use of the Delphi method is associated with some limita tions that might also play a role in other interview techniques. A common point of criticism circles around the selection of the participating experts. There are no binding rules on how to identify and select the relevant experts in a field of interest. Thus, the initiator of a Delphi panel has to ensure a thorough selection process of the panelists [31] . In the present study, the identification of relevant experts was based on an academic background in the therapy of MTC. 13 experts were invited to the panel, of which 9 finally took part in the survey. As MTC is a rare condition, only a very limited number of clinicians will take care of these patients in Germany. Hence, reflecting prevalence numbers for this indication with the number of pa tients treated by the panel members, it should be fair to state that the panel is representative.
At the time of the Delphi panel, no systemic therapy was approved for the treatment of MTC. With the approval of vandetanib in February 2012 in Germany, a tyrosine kinase in hibitor became available for the treatment of advanced MTC. Considering this new treatment option, the results of the panel and BSC may be different in the future. This limitation also applies to the calculated costs, which may change with this treatment option available.
Conclusions
There was consistent agreement within the panel on the prevalence and the structure of treatment options within BSC of patients with advanced MTC. Management of advanced MTC is performed in accordance with published guidelines; special emphasis is put on the treatment and prevention of tumorrelated symptoms. Substantial costs occur for BSC from the perspective of the healthcare system; these costs are comparable to those for BSC in other tumor entities. More over, the results of this study can be used as a basis for future health economic evaluations in this setting.
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